Michael Mina - 31 Jul 2026 Form 4 Insider Report for Invivyd, Inc. (IVVD)

Reporting relationship: CMO and Chief Epidemiologist
Issuer ticker: IVVD
Reported as of: 31 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Aug 2026, 16:15:07 UTC
Prior SEC filing: 16 May 2023
Source filing: View source filing
Reporting owner signature: /s/ Jill Andersen attorney-in-fact for Michael Mina

Key filing fact

Michael Mina filed Form 4 for Invivyd, Inc. (IVVD) on 04 Aug 2026.

Key facts

This page summarizes Michael Mina's Form 4 filing for Invivyd, Inc. (IVVD).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Aug 2026, 16:15.

Change

Previous filing in this sequence was filed on 16 May 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001856954 Primary reporting owner

Mina Michael

Relationship: CMO and Chief Epidemiologist
Address: C/O INVIVYD, INC., 209 CHURCH STREET, NEW HAVEN
Signature: /s/ Jill Andersen attorney-in-fact for Michael Mina
Signature date: 04 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IVVD transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +1,125,000
Change %
Price: $0.000000^*
Shares after: 1,125,000
Date: 31 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,125,000
Exercise price: $0.5350
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option vests over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the grant date of July 31, 2026 and the remaining 75% of the shares subject to the option vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, subject to the Reporting Person's continuous service as of each vesting date.